SCHEMBL17479324

SCHEMBL17479324

NCCCN(C1CCCCC1)S(=O)(=O)c1cccc(-c2nc3cccc(O)c3o2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ MAPT P10636 4/20 0.36
▸ THRB P10828 2/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ ALDH1A1 P00352 5/20 0.36
▸ NPSR1 Q6W5P4 3/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ HPGD P15428 2/20 0.36
▸ HTT P42858 2/20 0.36
▸ LMNA P02545 2/20 0.36
▸ MTNR1A P48039 1/20 0.35
▸ MTNR1B P49286 1/20 0.35
▸ USP2 O75604 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17479726 0.87 TSHR (0.41) TSHRMAPK1HSD17B10KMT2AMAPT
SCHEMBL17479705 0.86 HSD17B10 (0.42) TSHRMAPK1HSD17B10MEN1KMT2A
SCHEMBL17479707 0.86 PSEN1 (0.39) TSHRMAPK1HSD17B10MEN1KMT2A
SCHEMBL17479697 0.82 MAPK1 (0.38) TSHRMAPK1HSD17B10KMT2AMAPT
SCHEMBL17479006 0.82 SMN1; SMN2 (0.43) TSHRMAPK1HSD17B10KMT2AMAPT
SCHEMBL17479172 0.79 SMN1; SMN2 (0.42) TSHRMAPK1HSD17B10KMT2AMAPT
SCHEMBL17479698 0.76 SMN1; SMN2 (0.44) TSHRMAPK1HSD17B10KMT2AMAPT
SCHEMBL17479667 0.76 MMP2 (0.45) TSHRMAPK1HSD17B10MEN1KMT2A
SCHEMBL17479756 0.76 MAPT (0.51) TSHRMAPK1HSD17B10MEN1KMT2A
SCHEMBL17479795 0.75 SMN1; SMN2 (0.45) TSHRMAPK1HSD17B10KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3174859-B1 FLT3 RECEPTOR ANTAGONISTS INST NAT SANTE RECH MED (FR) 2020-04-29 — — EP claimed
US-10065937-B2 FLT3 receptor antagonists INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2018-09-04 — — US claimed
US-20170233354-A1 FLT3 RECEPTOR ANTAGONISTS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2017-08-17 — — US claimed
EP-3174859-A1 FLT3 RECEPTOR ANTAGONISTS INSERM - Institut National de la Santé et de la Recherche Médicale (FR) 2017-06-07 — — EP claimed
WO-2016016370-A1 FLT3 RECEPTOR ANTAGONISTS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-02-04 — — WO claimed
CN-107001283-B FLT3 receptor antagonists 国家健康与医学研究院 2021-05-25 — — CN disclosed
US-20200171022-A1 FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-06-04 — — US disclosed
EP-3174859-B1 FLT3 RECEPTOR ANTAGONISTS INST NAT SANTE RECH MED (FR) 2020-04-29 — — EP disclosed
EP-3624780-A1 FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-03-25 — — EP disclosed
WO-2018211018-A1 FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2018-11-22 — — WO disclosed
US-10065937-B2 FLT3 receptor antagonists INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2018-09-04 — — US disclosed
US-20170233354-A1 FLT3 RECEPTOR ANTAGONISTS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2017-08-17 — — US disclosed
EP-3174859-A1 FLT3 RECEPTOR ANTAGONISTS INSERM - Institut National de la Santé et de la Recherche Médicale (FR) 2017-06-07 — — EP disclosed
WO-2016016370-A1 FLT3 RECEPTOR ANTAGONISTS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-02-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233354-A1 FLT3 RECEPTOR ANTAGONISTS FLT3, CSF1R, CSF3R TSHR 69/4885MAPK1 1387/4885HSD17B10 4204/4885
US-10065937-B2 FLT3 receptor antagonists FLT3, CSF1R, CSF3R TSHR 69/4885MAPK1 1387/4885HSD17B10 4204/4885
US-20200171022-A1 FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS FLT3, CSF1R, OPRL1 TSHR 2361/4885MAPK1 601/4885HSD17B10 4833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback